| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kwang-Rok Kim, Sang-Dal Rhee, Hee Youn Kim, Won Hoon Jung, Sung-Don Yang, Sung Soo Kim, Jin Hee Ahn, Hyae Gyeong Cheo. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity. European journal of pharmacology. vol 518. issue 1. 2005-09-23. PMID:16106524. |
administration of kr-62436 to c57bl/6j mice either orally or subcutaneously resulted in the suppression of plasma dpp-iv activity, increase in intact glp-1 and insulin levels in plasma. |
2005-09-23 |
2023-08-12 |
mouse |
| Eugenio D'Amico, Hongxiang Hui, Nasif Khoury, Umberto Di Mario, Riccardo Perfett. Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. Journal of molecular endocrinology. vol 34. issue 2. 2005-09-22. PMID:15821104. |
finally, to study whether the antiapoptotic action of glp-1 was a function of its effect on insulin secretion, or rather it was a direct effect of glp-1, cells were cultured with or without diazoxide or exendin-9. |
2005-09-22 |
2023-08-12 |
mouse |
| L Bai, G Meredith, B E Tuc. Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079260. |
addition of glp-1 (100 nm) and nicotinamide (10 mm) at stage 5 resulted in a 50% and 48% increase in insulin content and c-peptide secretion respectively compared with nicotinamide alone. |
2005-09-22 |
2023-08-12 |
mouse |
| L Bai, G Meredith, B E Tuc. Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079260. |
it is concluded that both glp-1 and exendin-4 enhance the level of expression of insulin in glucose-responsive insulin-producing cells derived from the r1 mesc line. |
2005-09-22 |
2023-08-12 |
mouse |
| Colin W Hay, Elaine M Sinclair, Giovanna Bermano, Elaine Durward, Mohammad Tadayyon, Kevin Dochert. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079261. |
glucagon-like peptide-1 (glp-1) is a peptide hormone secreted from the enteroendocrine l-cells of the gut and which acts primarily to potentiate the effects of glucose on insulin secretion from pancreatic beta-cells. |
2005-09-22 |
2023-08-12 |
human |
| Colin W Hay, Elaine M Sinclair, Giovanna Bermano, Elaine Durward, Mohammad Tadayyon, Kevin Dochert. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079261. |
previous studies on the mechanisms whereby glp-1 regulates insulin gene transcription have focused on the rat insulin promoter. |
2005-09-22 |
2023-08-12 |
human |
| Colin W Hay, Elaine M Sinclair, Giovanna Bermano, Elaine Durward, Mohammad Tadayyon, Kevin Dochert. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079261. |
the aim of this study was to determine whether the human insulin promoter was also responsive to glp-1, and if so to investigate the possible role of camp-responsive elements (cres) that lie upstream (cre1 and cre2) and downstream (cre3 and cre4) of the transcription start site. |
2005-09-22 |
2023-08-12 |
human |
| Colin W Hay, Elaine M Sinclair, Giovanna Bermano, Elaine Durward, Mohammad Tadayyon, Kevin Dochert. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079261. |
glp-1 was found to stimulate the human insulin promoter, albeit to a lesser degree than the rat insulin promoter. |
2005-09-22 |
2023-08-12 |
human |
| Reawika Chaikomin, Selena Doran, Karen L Jones, Christine Feinle-Bisset, Deirdre O'Donovan, Christopher K Rayner, Michael Horowit. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American journal of physiology. Endocrinology and metabolism. vol 289. issue 3. 2005-09-21. PMID:15886226. |
initially more rapid small intestinal glucose delivery increases plasma insulin, gip, and glp-1 but does not improve overall glycemia in healthy subjects. |
2005-09-21 |
2023-08-12 |
human |
| Reawika Chaikomin, Selena Doran, Karen L Jones, Christine Feinle-Bisset, Deirdre O'Donovan, Christopher K Rayner, Michael Horowit. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American journal of physiology. Endocrinology and metabolism. vol 289. issue 3. 2005-09-21. PMID:15886226. |
the latter is also dependent on stimulation of insulin secretion by glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1). |
2005-09-21 |
2023-08-12 |
human |
| Reawika Chaikomin, Selena Doran, Karen L Jones, Christine Feinle-Bisset, Deirdre O'Donovan, Christopher K Rayner, Michael Horowit. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American journal of physiology. Endocrinology and metabolism. vol 289. issue 3. 2005-09-21. PMID:15886226. |
between t = 0 and 75 min, plasma insulin, gip, and glp-1 were higher with the variable infusion. |
2005-09-21 |
2023-08-12 |
human |
| J F Gautier, S Fetita, E Sobngwi, C Salaün-Marti. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes & metabolism. vol 31. issue 3 Pt 1. 2005-09-21. PMID:16142014. |
in humans, the incretin effect is mainly caused by two peptide hormones, glucose-dependent insulin releasing polypeptide gip, and glucagon-like peptide-1 glp-1. |
2005-09-21 |
2023-08-12 |
Not clear |
| J F Gautier, S Fetita, E Sobngwi, C Salaün-Marti. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes & metabolism. vol 31. issue 3 Pt 1. 2005-09-21. PMID:16142014. |
in addition to its effects on insulin secretion, glp-1 exerts other significant actions, including stimulation of insulin biosynthesis, inhibition of glucagon secretion, inhibition of gastric emptying and acid secretion, reduction of food intake, and trophic effects on the pancreas. |
2005-09-21 |
2023-08-12 |
Not clear |
| Guoxin Kang, Oleg G Chepurny, Michael J Rindler, Leon Collis, Zina Chepurny, Wen-Hong Li, Mark Harbeck, Michael W Roe, George G Hol. A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic beta cells. The Journal of physiology. vol 566. issue Pt 1. 2005-09-16. PMID:15860526. |
we propose that second messenger coincidence detection of this type may explain how glp-1 interacts with beta cell glucose metabolism to stimulate insulin secretion. |
2005-09-16 |
2023-08-12 |
mouse |
| A Mari, W M Sallas, Y L He, C Watson, M Ligueros-Saylan, B E Dunning, C F Deacon, J J Holst, J E Fole. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism. vol 90. issue 8. 2005-09-14. PMID:15886245. |
although glp-1 is known to stimulate insulin secretion, vildagliptin does not affect plasma insulin levels in diabetic patients, suggesting that more sophisticated measures are necessary to ascertain the influence of vildagliptin on beta-cell function. |
2005-09-14 |
2023-08-12 |
Not clear |
| Juris J Meier, Guido Kemmeries, Jens J Holst, Michael A Nauc. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. vol 54. issue 7. 2005-09-13. PMID:15983224. |
glucagon-like peptide 1 (glp-1) has been proposed to act as an incretin hormone due to its ability to enhance glucose-stimulated insulin secretion. |
2005-09-13 |
2023-08-12 |
human |
| Juris J Meier, Guido Kemmeries, Jens J Holst, Michael A Nauc. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. vol 54. issue 7. 2005-09-13. PMID:15983224. |
because glp-1 also decelerates gastric emptying, it physiologically reduces rather than augments postprandial insulin secretory responses. |
2005-09-13 |
2023-08-12 |
human |
| Juris J Meier, Guido Kemmeries, Jens J Holst, Michael A Nauc. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. vol 54. issue 7. 2005-09-13. PMID:15983224. |
therefore, we aimed to antagonize the deceleration of gastric emptying by glp-1 to study its effects on insulin secretion after a meal. |
2005-09-13 |
2023-08-12 |
human |
| Juris J Meier, Guido Kemmeries, Jens J Holst, Michael A Nauc. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. vol 54. issue 7. 2005-09-13. PMID:15983224. |
capillary and venous blood samples were drawn for the determination of glucose (glucose oxidase), insulin, c-peptide, glp-1, glucagon, gastric inhibitory polypeptide (gip), and pancreatic polypeptide (specific immunoassays). |
2005-09-13 |
2023-08-12 |
human |
| Juris J Meier, Guido Kemmeries, Jens J Holst, Michael A Nauc. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. vol 54. issue 7. 2005-09-13. PMID:15983224. |
insulin secretory responses to the meal were lower during glp-1 administration (p < 0.05 vs. placebo). |
2005-09-13 |
2023-08-12 |
human |